Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT05581160 Recruiting - Clinical trials for Chlamydia Trachomatis Infection

Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)

NGS-IST
Start date: July 11, 2022
Phase: N/A
Study type: Interventional

The main objective of the study will be to assess the performance of the Next-Generation-Sequencing (NGS) diagnostics of Chlamydia trachomatis and Neisseria gonorrhoeae compared to reference techniques.

NCT ID: NCT05581017 Completed - Clinical trials for Surgical Site Infection

Association of Cephalosporin Resistance and Surgical Site Infections in Patients Undergoing Pancreaticoduodenectomy

Start date: June 16, 2020
Phase:
Study type: Observational

Preoperative biliary drainage predisposes the bile to be contaminated with bacteria of the duodenum. These bacteria colonizing the bile are a potential source for surgical site infections after pancreaticoduodenectomy and many international guidelines recommend the use of cephalosporines as microbial prophylaxis before surgery. The aim of this study was to assess the incidence of bacteria in bile, their resistance profiles and association to surgical site infections in relation to timing of surgery after preoperative biliary drainage in order to better guide antibiotic use.

NCT ID: NCT05578196 Recruiting - Sepsis Clinical Trials

Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.

Start date: September 4, 2022
Phase: N/A
Study type: Interventional

Fecal microbial transplantation is to transplant functional microbiota from the feces of healthy people into the gastrointestinal tract of patients, reconstruct new intestinal microbiota, and realize the treatment of intestinal and extra-intestinal diseases. Compared with ordinary commercial probiotics, FMT is more consistent with the composition of the intestinal microecological structure and can recover intestinal flora to the maximum extent and faster. FMT increases intestinal bacteria production function and helps to restore the systemic immune response so that sepsis pathogens are removed. The aim of this trial was to investigate the clinical effect of FMT in the treatment of patients with severe infections.

NCT ID: NCT05577065 Recruiting - Clinical trials for Upper Respiratory Tract Infections

A Study to Assess the Effect of a Probiotic on Upper Respiratory Tract Infections in Healthy Children

KLEENEX
Start date: January 30, 2023
Phase: N/A
Study type: Interventional

This study evaluates the efficacy of a single strain probiotic on the incidence, duration and severity of upper respiratory tract infections in healthy, school-age children.

NCT ID: NCT05576194 Completed - Clinical trials for Cardiac Implantable Electronic Device Infection

Taurolidine Containing Antimicrobial CIED Wash to Prevent Infection

Start date: January 1, 2020
Phase:
Study type: Observational

From January 1st 2020, any CIED procedure conducted with adjunct TauroPaceā„¢ CIED and pocket irrigation is enrolled in a consecutive manner and followed up in one centre. Follow-up is prospectively. Before that date any CIED procedure conducted with adjunct antispetic pocket and CIED irrigation is evaluated retrospectively to form a comparable group.

NCT ID: NCT05575427 Recruiting - Hospital Infections Clinical Trials

Efficacy of Combination Therapy With Minocycline for Treatment of Stenotrophomonas Maltophilia Infections

Start date: November 24, 2022
Phase: Phase 4
Study type: Interventional

The objective of the study is to evaluate the efficacy of minocycline for treatment Stenotrophomonas maltophilia infection. The hypothesis of study is the combination therapy with minocycline would be better than the monotherapy for treatment Stenotrophomonas maltophilia infection.

NCT ID: NCT05575050 Completed - Clinical trials for Microbial Colonization

Impact of Teeth Brushing in Ventilated COVID-19 Patients.

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The aims of this study were: 1. Observation of dynamics in oral microbiota and its association with the incidence of HAIs and VAP in mechanically ventilated COVID-19 patients in an ICU setting 2. Evaluation of the incidence of HAIs and VAP and their association with oral bacteriobiota in mechanically ventilated COVID-19 patients in an ICU setting 3. Assessment of impact of different oral hygienic procedures on oral microbiota, the incidence of HAI and patients' safety in mechanically ventilated COVID-19 patients in an ICU setting approaches to oral care in an ICU setting Intervention of oral hygienic procedures implemented in study: Patients were divided into 2 groups depending on the oral care procedure: 1. Standard oral procedure (cleaning and moisturizing of oral cavity, suction of excess fluid) 2. Extended oral procedure (cleaning and moisturizing of oral cavity, teeth brushing, suction of excess fluid)

NCT ID: NCT05573334 Recruiting - Clinical trials for Urinary Tract Infections

Vaginal Care System for Menopausal Women With Urinary Tract Infections

Start date: July 10, 2023
Phase: N/A
Study type: Interventional

Menopausal women have an increased risk of recurrent urinary tract infections. This is likely due in part to hormonal changes occurring during menopause. As estrogen falls, the vaginal microbiome shifts from a healthy one to a less healthy one. Because the vagina is close to the urethra, this vaginal microbiome shift contributes to a loss of protection against urinary tract infections (UTIs). The investigators are asking whether improving the vaginal microbiome using an over-the-counter vaginal hygiene system can reduce frequency of recurrent UTI in menopausal women.

NCT ID: NCT05569330 Active, not recruiting - Diarrhea Clinical Trials

Effect of Aerosol Filtering on Infectious Diseases in Day Care

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Effect of aerosol flitration and removal on typical infectious diseases such as upper respiratory tract infectinos is studied in day care. Many filtration methods such as filters and electrical filtering are used to remove aerosol particles from room air.

NCT ID: NCT05568953 Recruiting - Infectious Disease Clinical Trials

An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity

Start date: September 28, 2022
Phase: Phase 2
Study type: Interventional

We hypothesize that a high CD4+ and CD8+ T cell count will reduce viremia upon challenge with a structurally heterologous virus, and correspondingly result in reduced magnitude of host response to challenge infection. Primary Objective: To compare, after challenge with a structurally heterologous vaccine, the differences in levels of viremia between healthy adults who received primary vaccination with either YF17D vaccine, chimeric JE-YF17D vaccine, or inactivated JE vaccine. 58 subjects will be randomised into 1 of 2 arms (Arm B1 and Arm B2) in a 1:1 ratio, in a double-blind fashion. Subjects in Arm B1 will receive JE-YF17D vaccine (Imojev, Sanofi Pasteur) on Day 0 followed by YF17D vaccine (Stamaril, Sanofi Pasteur) on Day 28. Subjects in Arm B2 will receive Stamaril on Day 0 followed by Imojev on Day 28. Arm B3 will be conducted as a separate single-arm open label design in 14 subjects. Subjects in Arm B3 will receive inactivated JE vaccine (Ixiaro, Valneva) on Day 0 followed by Stamaril on Day 28. The rationale for these three study arms is as follows: Arm B1 will show the impact low levels of viremia, and the resultant low levels of virus-specific CD4+ and CD8+ T cells, would have on YF17D infection. In contrast, YF17D vaccination in Arm B2 would produce high levels of viremia, and in turn high levels virus-specific T cells, thus likely ameliorating JE-YF17D infection. Arm B3 will serve as the control arm, as vaccination with inactivated JE vaccine would not produce any YF17D-specific T cell response. Notably, the first vaccination in Arms B1 and B2 would also provide the viremia response in the absence of virus-specific T cells, which would serve as a reference point to interpret the outcome of the second vaccination.